MedTrace Logo

Validation of a Digital Self-Administered Cognitive Screening Tool: MoCA-XpressO

NCT05879562 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-05-30

No results posted yet for this study

Summary

The investigators conducted a validation study for the Montreal Cognitive Assessment (MoCA)-XpressO compared to the digital-MoCA test (version 8.1) as the gold standard. Participants were recruited from the MoCA clinic and a family practice. Ethics approval was received, and all participants provided informed consent. A crossover study design was applied to the MoCA-XpressO and the digital-MoCA test; participants were randomized for the order of administration. The investigators only recruited participants who did not complete a MoCA test during the 3 months prior to the study. A logistic regression model was built, and the accuracy of the model was evaluated by the sensitivity, specificity, and area under the Receiver Operating Characteristic (ROC) curve.

Conditions

Interventions

DIAGNOSTIC_TEST

MoCA-Xpresso

MoCA-Xpresso is a home-based, self-administered digital cognitive screening tool, based on a tablet device.

Sponsors & Collaborators

  • MoCA Clinic and Institute

    lead OTHER

Principal Investigators

  • Ziad Nasreddine, MD · MoCA Clinic and Institute, 4896 Taschereau Blvd bureau 230, Greenfield Park, Quebec J4V 2J2

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2023-06-30
Completion
2023-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05879562 on ClinicalTrials.gov